Reviewing MeiraGTx (NASDAQ:MGTX) and Krystal Biotech (NASDAQ:KRYS)

MeiraGTx (NASDAQ:MGTX) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares MeiraGTx and Krystal Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	-651.19%	-122.82%	-48.11%
Krystal Biotech	N/A	-5.74%	-5.45%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for MeiraGTx and Krystal Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	0	2	0	3.00
Krystal Biotech	0	1	9	0	2.90

MeiraGTx presently has a consensus price target of $22.50, suggesting a potential upside of 417.24%. Krystal Biotech has a consensus price target of $187.89, suggesting a potential downside of 6.82%. Given MeiraGTx’s stronger consensus rating and higher possible upside, equities research analysts plainly believe MeiraGTx is more favorable than Krystal Biotech.

Risk and Volatility

MeiraGTx has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Krystal Biotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are held by institutional investors. 8.4% of MeiraGTx shares are held by company insiders. Comparatively, 14.1% of Krystal Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares MeiraGTx and Krystal Biotech’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$8.12 million	34.44	-$84.03 million	($1.17)	-3.72
Krystal Biotech	$166.23 million	34.64	$10.93 million	$1.87	107.82

Krystal Biotech has higher revenue and earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Summary

Krystal Biotech beats MeiraGTx on 11 of the 14 factors compared between the two stocks.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.